Related Experiment Video

Updated: May 23, 2026

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina
07:32

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina

Published on: June 23, 2014

Neuroprotection in vascular dementia: a future path

Ingmar Skoog1, Amos D Korczyn, Alla Guekht

  • 1The Sahlgrenska Academy, University of Gothenburg, Sweden.

Journal of the Neurological Sciences
|April 5, 2012
PubMed

Insights

Cognitive disorders are increasing. A new trial investigates Actovegin for post-stroke cognitive impairment, offering potential disease-modifying effects beyond current Alzheimer's disease treatments.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Cognitive disorders pose a growing global health challenge, exacerbated by aging populations and lifestyle changes.
  • Vascular dementia presents complex pathology, often co-occurring with other neurodegenerative diseases, limiting current treatment options.
  • Existing Alzheimer's disease medications demonstrate limited efficacy for vascular dementia.

Purpose of the Study:

  • To investigate the efficacy and disease-modifying potential of Actovegin in patients with post-stroke cognitive impairment.
  • To explore Actovegin's neuroprotective mechanisms and therapeutic benefits in a specific cognitive decline population.

Main Methods:

  • A new clinical trial designed to assess Actovegin's effects in post-stroke cognitive impairment.
  • Leveraging prior experimental data on Actovegin's cellular effects and neuroprotection.
  • Building upon positive outcomes from trials involving mixed dementia populations.

Main Results:

  • Experimental studies indicate Actovegin possesses neuroprotective properties.
  • Clinical trials in mixed dementia populations suggest potential benefits.
  • Actovegin is a hemodialysate derived from calf blood with demonstrated effects on cellular processes.

Conclusions:

  • Actovegin shows promise as a multimodal therapy for cognitive disorders.
  • Further research is warranted to establish Actovegin's efficacy in post-stroke cognitive impairment.
  • The study aims to provide a novel therapeutic strategy for vascular dementia and related cognitive deficits.

More Related Videos

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis05:12

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis

Published on: November 22, 2024

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...